GNLX: Genelux Corp Forward P/S Multiple

Corporate emblem and logo of Genelux (GNLX)

The forward P/S dynamics demonstrate the long-term valuation trend of Genelux Corporation (GNLX), where 8720.40 becomes the new value for this metric. Genelux Corporation (GNLX) creates viral platforms to combat solid tumors by activating the patient's immunity. The innovative Olvi-Vec ecosystem provides patent protection and connectivity with medical centers. The business is currently actively developing a line of drugs for selective cancer immunotherapy.

GNLX Genelux Corp.: Market Cap to Future Revenue Ratio in the range 04/28/2023 - 11/17/2026

Summary analytical data breakdowns for Genelux Corp. (GNLX)

- stock price and consensus target price:
- market capitalization information:
Comprehensive company analysis:genelux.com GNLX
Original product of Genelux

Bioprocess automation at Genelux Corporation (GNLX) minimizes operational risks, which directly impacts expected revenue and shapes the projected P/S valuation. This indicator compares current market capitalization with future earnings, allowing investors to determine whether the price includes a premium for technological leadership or if the asset has become overvalued, thereby reducing the business's margin of safety.